National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Polatuzumab vedotin (Polivy®). HTA ID: 22043

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

NCPE Assessment Process Complete
Rapid review commissioned 27/06/2022
Rapid review completed 27/07/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care.